FDA Pulls 16 Unused Generic Drug Approvals
Published Date: 6/3/2026
Notice
Summary
The FDA is officially pulling the plug on 16 generic drug approvals because the companies told them these medicines aren’t being sold anymore. This change kicks in on July 6, 2026, and it won’t stop companies from trying again later if they want. If you’re a drug maker or just curious, this means fewer old approvals cluttering the books and a cleaner, fresher drug list.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 2 costs, 0 mixed.
FDA Withdraws 16 Generic Approvals
The FDA is withdrawing approval of 16 abbreviated new drug applications (ANDAs) at the request of the applicants. This withdrawal takes effect on July 6, 2026 and applies to the entire application and all strengths and dosage forms.
Post-Withdrawal Sales Are Prohibited
After July 6, 2026, introducing into interstate commerce any of the listed products without an approved ANDA violates sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act. Firms that distribute or attempt to market these products without approval would be acting unlawfully.
Existing Inventory May Still Be Dispensed
Drug products listed in the notice that are in inventory on July 6, 2026 may continue to be dispensed until the inventories are depleted or the products reach their expiration dates, whichever occurs first. This allows existing stock at pharmacies or wholesalers to be used up after the approval withdrawal date.
Withdrawals Are Without Prejudice
The FDA states that withdrawal of approval under 21 CFR 314.150(c) is without prejudice to refiling. That means applicants may refile ANDAs later if they choose to pursue approval again.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073 — Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-14573 — Food Standards of Identity Modernization; Pasteurized Orange Juice
The FDA is updating the rules for pasteurized orange juice by lowering the minimum sugar content and allowing up to 15% of a new type of citrus juice. This change helps juice makers, especially in Florida, keep up with modern practices without raising costs. The new rules kick in on August 19, 2026, giving producers time to adjust.
2026-14434 — Agency Information Collection Activities; Proposed Collection; Comment Request; Requirements for Cosmetic Products
The FDA wants your thoughts on new info they might collect about cosmetic products. This affects companies making or selling cosmetics, who may need to share more details soon. You’ve got until September 15, 2026, to send in your comments—no cost yet, just your voice!
2026-14438 — Agency Information Collection Activities; Proposed Collection; Comment Request; Infant Formula Requirements
The FDA wants your thoughts on how they collect info about infant formula rules, like labeling, quality checks, and recordkeeping. This affects infant formula makers who must follow these rules and use a new electronic form to report info. You’ve got until September 15, 2026, to share your comments—no cost changes yet, just a chance to improve how info is gathered!
2026-14441 — Agency Information Collection Activities; Proposed Collection; Comment Request; Accreditation Scheme for Conformity Assessment Program
The FDA wants your thoughts on a plan to improve how they check if medical products meet safety rules. This affects companies making medical devices and could change how they prove their products are safe. You’ve got until September 15, 2026, to share your ideas—no cost changes yet, just a chance to help shape the process!
Previous / Next Documents
Previous: 2026-11060 — Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities-Questions and Answers; Revised Draft Guidance for Industry; Availability
The FDA just released a revised draft guide to help drug and device makers share important cost and coverage info with insurance companies and similar groups. This update clears up how to talk about approved products, unapproved products, and new uses, making it easier for everyone to understand the rules. Companies should send their feedback by August 3, 2026, so the FDA can finalize the guide—potentially speeding up coverage decisions and saving money.
Next: 2026-11063 — Proposed Exemption Involving the Abiomed Retirement Savings Plan Located in Danvers, MA
The Abiomed Retirement Savings Plan in Danvers, MA, wants permission to hold special financial rights called contingent value rights (CVRs) and get payments from them. Without this okay, these moves would break some important retirement rules. If approved, the exemption starts retroactively from November 15, 2022, and folks have until July 20, 2026, to share their thoughts or ask for a hearing.